Hepatic Encephalopathy Epidemiology Forecast 2025-2034

Hepatic encephalopathy is characterized by a range of neuropsychiatric abnormalities and is often linked with preexisting liver conditions. According to a population-based study, around 44% of patients with cirrhosis are likely to develop hepatic encephalopathy within a 5-year period.

Hepatic Encephalopathy Epidemiology Forecast Report Coverage

The “Hepatic Encephalopathy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hepatic encephalopathy. It projects the future incidence and prevalence rates of hepatic encephalopathy across various populations. The study covers age, gender, and type as major determinants of the hepatic encephalopathy-affected population. The report highlights patterns in the prevalence of hepatic encephalopathy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hepatic encephalopathy in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hepatic Encephalopathy Disease Overview

Hepatic encephalopathy refers to a brain dysfunction that is caused by liver dysfunction. It occurs due to the failure of the liver to filter toxins from the blood. The onset of this brain disorder can be gradual or sudden. Early symptoms include confusion, forgetfulness, personality or mood changes, and breath with a sweet or musty odor, among others. On the other hand, advanced symptoms are shaking of the arms or hands, slurred speech, and disorientation. Hepatic encephalopathy can prove to be fatal without treatment.

Hepatic Encephalopathy: Treatment Overview

Treatment for hepatic encephalopathy may include medications to treat infections, therapeutic interventions for kidney issues, procedures to stop active bleeding, and stopping the intake of drugs that depress central nervous system function. After the precipitating factors are addressed, the treatment approach is focused on lowering ammonia levels and other toxins in the blood. Lactulose and antibiotics are usually prescribed to eliminate or reduce the production of toxins.

Epidemiology

The hepatic encephalopathy epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for hepatic encephalopathy by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatic encephalopathy and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per a population-based study around 44% of cirrhosis patients may develop hepatic encephalopathy over the course of 5 years.
• According to a 2019 study with over 9000 newly diagnosed cirrhosis patients, it was revealed that nearly one-third had decompensated cirrhosis. Further, out of this decompensated cirrhosis patient pool, around 51% experienced hepatic encephalopathy.
• Hepatic encephalopathy is estimated to occur in approximately 40% of patients with cirrhosis and is found to be more common in people with portal hypertension and alcohol-related liver disease (ALD), according to Louissaint, Jeremy et al. (2022).
• The American Liver Foundation states that around 7 in 10 people with cirrhosis tend to develop minimal hepatic encephalopathy (Grade 0).

Country-wise Hepatic Encephalopathy Epidemiology

The hepatic encephalopathy epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hepatic encephalopathy differs between countries owing to the variation in the prevalence of underlying liver conditions, such as cirrhosis, viral hepatitis (HBV and HCV), alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Healthcare access, patterns of alcohol consumption, and genetic factors also influence the prevalence and incidence of hepatic encephalopathy in various regions. According to a longitudinal cohort-based study published in the International Journal of Hepatology (2021), approximately 202,000 patients had hepatic encephalopathy in the United States in 2018.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hepatic encephalopathy based on several factors.
• Hepatic Encephalopathy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of hepatic encephalopathy are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hepatic encephalopathy epidemiology in the 8 major markets?
• What will be the total number of patients with hepatic encephalopathy across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hepatic encephalopathy in the 8 major markets in the historical period?
• Which country will have the highest number of hepatic encephalopathy patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hepatic encephalopathy during the forecast period of 2025-2034?
• What are the currently available treatments for hepatic encephalopathy?
• What are the disease risks, signs, symptoms, and unmet needs of hepatic encephalopathy?

This product will be delivered within 3-5 business days.